Dr. Sheppard speaks about the future of pharmacological therapy for dry eye disease associated with meibomian gland dysfunction. This program was recorded prior to the approval of perfluorohexyloctane ophthalmic solution (formerly known as NOV03).
This activity is supported by an unrestricted educational grant from Bausch + Lomb.
Upon completion of this activity, the participant should be able to:
Provided by Evolve Medical Education 
Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Evolve designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
John D. Sheppard, MD, MMSc, FACS
Founding Partner, Virginia Eye Consultants
Professor of Ophthalmology, Microbiology, Molecular Biology
Ophthalmology Residency Research Director
Eastern Virginia Medical School
Division Medical Director, EyeCare Partners
Medical Director
Lions Medical Eye Bank of Eastern Virginia
Norfolk, VA
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
John D. Sheppard, MD, MMSc, FACS,has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Aerie Pharmaceuticals, Alcon, Aldeyra Therapeutics, Allergan, Allysta Pharmaceuticals, Avedro, Bausch + Lomb, BioTissue, Bruder Healthcare, Clementia Pharmaceuticals, Dompé, EyeGate, EyePoint Pharmaceuticals, Glaukos, Hovione, Johnson & Johnson Vision, Kala Pharmaceuticals, Lacri Sciences, LayerBio, Mallinckrodt, Novaliq, Novartis, Noveome Biotherapeutics, Ocular Therapeutix, Omeros, Oyster Point Pharma, Quidel, ScienceBased Health, Shire, Sun Pharma, Takeda Pharmaceuticals USA, TearLab, Tear Solutions, and TopiVert. Grant/Research Support: Alcon, Bausch + Lomb, Chengdu Kanghong Biotechnology, Clearside Biomedical, EyeGate, Hovione, Kala Pharmaceuticals, Mallinckrodt, and Visus Pharmaceuticals. Speaker’s Bureau: Alcon, Bausch + Lomb, BioTissue, Dompé, and Mallinckrodt. Shareholder: Claris Bio, Doctors Optimal Formula, Eyedetec Medical, EyeRxResearch, Eyevance, Lacrisciences, LayerBio, Noveome Biotherapeutics, Oyster Point Pharma, ProVision Network, Rapid Pathogen Screening, Scientifically Developed Solutions, Strathspey Crowne, and TearLab.
The Evolve staff, planners and peer reviewer have no financial relationships with ineligible companies.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Bausch + Lomb.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Eric D. Donnenfeld, MD
Marjan Farid, MD
Jason J. Jones, MD
Eva I. Liang, MD, FACS
Carlton Yuen, MD
